The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving the way for its US launch. Celltrion’s Stelara biosimilar ustekinumab ...

The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges that it has yet to make the most of these drugs. That was certainly one of the ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

How to Add Fingerprint Authentication to Your Windows 11 Computer Your email has been sent You can easily add a fingerprint reader to your computer if one isn't already built in. If you’ve ...

How do you dust a star for fingerprints? It's certainly a strange question, but a team of researchers think they have the answer. Their findings could help us better understand how planets are born.

Executive Director and Co-Founder of the Not-For-Profit U.S. Biosimilars Forum PBM reform did not make it into the final continuing resolution this past December. Now, time is of the essence for ...

The 19 sets of fingerprints collected from actor Saif Ali Khan's residence after the attempted burglary and knife attack on him do not match the fingerprints of the accused Shariful Islam ...

In 2025, the three largest pharmacy benefit managers are largely rejecting biosimilars from their formularies, with the exception of their own private-label medicines, Drug Channels reported Jan. 22.

Changes which come in on Sunday permit so-called "fingerprinting", which allows online advertisers to collect more data about users including their IP addresses and information about their devices.

Surveying the next 12 months, J&J expects to chart roughly 3% sales growth to $91.3 billion in 2025 by “overcoming headwinds associated with U.S. biosimilar entries for Stelara,” as well as ...